Corbus Pharmaceuticals Statistics
Share Statistics
Corbus Pharmaceuticals has 12.18M shares outstanding. The number of shares has increased by 16.07% in one year.
| Shares Outstanding | 12.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 10.89M |
| Failed to Deliver (FTD) Shares | 65 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 2.65M, so 21.76% of the outstanding shares have been sold short.
| Short Interest | 2.65M |
| Short % of Shares Out | 21.76% |
| Short % of Float | 24.32% |
| Short Ratio (days to cover) | 9.64 |
Valuation Ratios
The PE ratio is -0.59 and the forward PE ratio is -3.42.
| PE Ratio | -0.59 |
| Forward PE | -3.42 |
| PS Ratio | 0 |
| Forward PS | 18.9 |
| PB Ratio | -3.79 |
| P/FCF Ratio | -0.72 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Corbus Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of -2.35.
| Current Ratio | 0.74 |
| Quick Ratio | 0.74 |
| Debt / Equity | -2.35 |
| Total Debt / Capitalization | 174.21 |
| Cash Flow / Debt | -2.23 |
| Interest Coverage | -15.42 |
Financial Efficiency
Return on equity (ROE) is 6.46% and return on capital (ROIC) is -322.45%.
| Return on Equity (ROE) | 6.46% |
| Return on Assets (ROA) | -1.58% |
| Return on Capital (ROIC) | -322.45% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.35M |
| Employee Count | 19 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 88.67% in the last 52 weeks. The beta is 2.56, so Corbus Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 2.56 |
| 52-Week Price Change | 88.67% |
| 50-Day Moving Average | 15.41 |
| 200-Day Moving Average | 35.68 |
| Relative Strength Index (RSI) | 28.89 |
| Average Volume (20 Days) | 311.80K |
Income Statement
| Revenue | n/a |
| Gross Profit | -31.17M |
| Operating Income | -45.08M |
| Net Income | -44.60M |
| EBITDA | -44.44M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -10.31 |
Balance Sheet
The company has 13.72M in cash and 20.88M in debt, giving a net cash position of -7.16M.
| Cash & Cash Equivalents | 13.72M |
| Total Debt | 20.88M |
| Net Cash | -7.16M |
| Retained Earnings | -436.68M |
| Total Assets | 164.17M |
| Working Capital | 149.26M |
Cash Flow
In the last 12 months, operating cash flow was -36.10M and capital expenditures 0, giving a free cash flow of -36.10M.
| Operating Cash Flow | -36.10M |
| Capital Expenditures | 0 |
| Free Cash Flow | -36.10M |
| FCF Per Share | -8.34 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -89.73% |
| FCF Yield | -25.8% |
Analyst Forecast
The average price target for CRBP is $62.5, which is 444% higher than the current price. The consensus rating is "Buy".
| Price Target | $62.5 |
| Price Target Difference | 444% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Feb 14, 2023. It was a backward split with a ratio of 1:30.
| Last Split Date | Feb 14, 2023 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | 3.23 |
| Piotroski F-Score | 3 |